news, journals and articles from all over the world.
The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.
Read moreA modified protein in benign-appearing meningiomas can reveal which are truly benign and which are more dangerous and require more aggressive treatment, researchers have discovered.
Read moreRoy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.
Read more
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC).
Read moreRoland Taylor, 69, has faced considerable struggles in life, at times battling homelessness and addiction. Two years ago, he felt a lump in his chest, but ignored it until he discovered that it had grown. He went to the doctor and was shocked to learn that he had breast cancer.
Read moreThe 2018 federal Right to Try Act allows patients with a life-threatening illness to be treated with drugs that have not yet been approved by the Food and Drug Administration (FDA). Many in the oncology community say Right to Try strips away important regulatory protections and view the move as a risky step bound to create ethical dilemmas for physicians whose goal is to guide patients toward safe and appropriate treatment decisions. Oncology is one field at the forefront of requests for unapproved drugs. An interdisciplinary team of bioethicists, oncologists, and lawyers from Penn Medicine and other institutions penned a commentary published online this week in the Journal of Clinical Oncology to offer recommendations to help oncologists navigate this new “Right to Try” world, while maintaining their ethical obligations to patients.
Read more
Modern advances in oncology have significantly improved cancer survival rates. However, personalized treatment methods are necessary, since tumors may behave differently for different patients. At the AVS 66th International Symposium and Exhibition, Cristina Canal, a researcher at Universitat Politècnica de Catalunya, will present cold plasmas as a promising tool for minimally invasive cancer therapy. She will discuss the benefits of using plasma jets for cancer therapy, and explain the use of different liquid media, hydrogels and their properties.
Read more
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology and Director of the Cancer Immunotherapy Program at Children’s Hospital of Philadelphia, has been elected into the National Academy of Medicine (NAM), effective Oct. 1, 2019.
Read more
Oncology nurse practitioner Anna Schwartz, a professor at Northern Arizona University, was a leader on the team that reviewed the latest scientific evidence and offered recommendations about the benefits of exercise for prevention, treatment, recovery and improved survival, which were shared this week in three publications.
Read moreNYU Langone Health has become one of 23 institutions selected to comprise the American Association for Thoracic Surgery’s Thoracic Surgery Oncology Group (TSOG). A North American thoracic surgery clinical trials network, TSOG aims to improve the understanding of thoracic oncologic diseases and enhance the care of patients.
Read more